Luxembourg (Europe)

Researchers from the University of Luxembourg found a new biomarker for colorectal cancer (CRC) that might improve therapy and survival rates of patients.

Biomarkers are measurable biological indicators for a specific disease, such as changes in the amounts of certain proteins that occur in combination with certain illnesses. Such biomarkers help physicians to diagnose a condition, identify the disease stage, and determine a patient’s risk for recurrence of the disease. This supports the doctor in choosing the best-fitting treatment plan.

Improved early diagnosis
For CRC, early detection and classification is especially important, as, for example, not all Stage II patients benefit from chemotherapy. Especially identifying patients at risk for recurrence during the early course of the disease might help clinicians. However, there are still too few prognostic markers for CRC known so that too many patients still suffer needlessly from side effects of the chemotherapy without having real benefits.

 

Learn more / En savoir plus / Mehr erfahren:

 

https://www.scoop.it/t/luxembourg-europe/?&tag=University+Luxembourg

 

https://www.scoop.it/t/luxembourg-europe/?&tag=Cancer